|
Patent landscape, scope, and claims: |
Patent 11,684,632: Analysis of Novel Drug Delivery Mechanisms
Patent 11,684,632, granted on June 27, 2023, to MediNova Technologies Inc., protects a novel drug delivery system designed to enhance therapeutic efficacy and patient compliance. The patent's claims focus on a specific formulation of a sustained-release oral dosage form containing an active pharmaceutical ingredient (API) encapsulated within a multi-layered polymer matrix. This technology aims to control the dissolution rate of the API, providing prolonged therapeutic action and reducing the frequency of administration.
What is the Core Invention of Patent 11,684,632?
The central innovation in patent 11,684,632 is a controlled-release oral dosage form. This formulation utilizes a specific combination of biodegradable polymers and a unique manufacturing process to achieve a predictable and sustained release profile of an encapsulated API over an extended period. The technology addresses limitations of immediate-release formulations, such as fluctuating plasma concentrations and the need for frequent dosing, which can lead to suboptimal treatment outcomes and reduced patient adherence.
What Specific Claims Are Covered by the Patent?
Patent 11,684,632 comprises 20 independent claims and 35 dependent claims. The independent claims define the essential elements of the invention, while dependent claims provide further limitations and specific embodiments.
Key Claim Categories:
-
Claim 1: The Dosage Form: This claim defines the core composition of the sustained-release dosage form. It specifies a unit dosage form comprising:
- An active pharmaceutical ingredient (API).
- A core material comprising a matrix of at least two distinct biodegradable polymers.
- A coating layer formed over the core material, comprising a semipermeable membrane.
- The ratio and specific types of polymers are critical to achieving the controlled release profile. The patent specifies a particular weight ratio of the polymers to ensure controlled swelling and erosion.
-
Claim 10: The Manufacturing Process: This claim outlines a method for manufacturing the dosage form. It involves:
- Forming a core comprising the API and the specified polymer matrix.
- Applying a semipermeable coating layer to the core.
- Creating at least one pore in the coating layer through a specific laser ablation or mechanical perforation technique.
- The pore formation is crucial for the osmotic pumping mechanism of drug release.
-
Claim 15: The Drug Release Profile: This claim defines the functional performance of the dosage form, specifically its drug release characteristics. It specifies that the dosage form releases the API in a substantially zero-order kinetic profile over a period of at least 12 hours when tested in vitro using USP apparatus 2 at 37°C and 100 rpm. A zero-order release means the drug is released at a constant rate, independent of the concentration of the drug in the dosage form.
-
Claim 18: Specific Polymer Combinations: This claim details specific combinations of biodegradable polymers that can be used in the core matrix, including combinations of poly(lactic-co-glycolic acid) (PLGA) with hydroxypropyl methylcellulose (HPMC) or poly(vinyl alcohol) (PVA). The molecular weight and lactide:glycolide ratio of PLGA are specified as critical parameters.
-
Claim 20: Osmotic Release Mechanism: This claim explicitly describes the osmotic mechanism by which the drug is released. The semipermeable membrane controls water ingress, creating osmotic pressure within the core, which then pushes the API out through the pore(s).
What are the Key Technical Specifications and Limitations?
The patent details several technical specifications that define the scope of the protected invention. These specifications are crucial for determining infringement and for understanding the boundaries of the intellectual property.
Critical Technical Parameters:
- Polymer Composition: The dosage form must contain at least two distinct biodegradable polymers. For instance, one polymer might be designed for swelling, and another for controlled erosion. A specific example cited involves a blend of PLGA with a lactide:glycolide ratio between 50:50 and 75:25, and a molecular weight range of 10,000 to 30,000 Da, combined with HPMC.
- Drug Loading: The patent specifies a drug loading range of 5% to 20% by weight of the core material. This range is optimized to achieve therapeutic plasma concentrations without compromising the structural integrity or release kinetics of the dosage form.
- Coating Thickness: The semipermeable membrane coating has a specified thickness range of 10 to 50 micrometers. This precise thickness is vital for regulating water flux into the core and thus controlling the release rate.
- Pore Size and Number: The pore(s) created in the semipermeable membrane have a diameter range of 50 to 200 micrometers. The number of pores is also limited, typically to one or two pores per dosage unit, to ensure controlled, sustained release.
- Release Kinetics: The primary functional parameter is the zero-order release of the API over a minimum of 12 hours. This is tested using standard in vitro dissolution methods. Variations in release profiles, such as a significant deviation from zero-order kinetics or release completion before 12 hours, would likely fall outside the scope of these claims.
- Biodegradability: The use of biodegradable polymers ensures that the dosage form components are broken down and eliminated from the body after drug release, minimizing potential accumulation or long-term foreign body reactions.
What is the Existing Patent Landscape for Similar Technologies?
The landscape for controlled-release drug delivery systems is extensive and highly competitive. Technologies employing osmotic pumps, matrix diffusion, and polymer erosion are well-established. MediNova's patent differentiates itself through its specific polymer combinations, pore formation technique, and the demonstrated achievement of a sustained zero-order release profile over an extended duration.
Key Differentiators in the Landscape:
- Osmotic Pump Systems: Many existing patents cover osmotic pump devices, often involving a semipermeable membrane and a laser-drilled orifice. However, patent 11,684,632 claims a specific internal matrix composition and manufacturing process for these pumps, distinct from established designs like those used in Alza Corporation's OROS technology.
- Matrix Diffusion Systems: These systems rely on drug diffusion through a porous or non-porous polymer matrix. The claims in 11,684,632 are more specific to an osmotic mechanism, differentiating it from purely diffusion-controlled systems.
- Biodegradable Polymer Formulations: While biodegradable polymers are widely used, the specific combinations and ratios claimed, along with their integration into a precise osmotic delivery system, form the core of MediNova's intellectual property.
- Release Rate Control: Achieving a consistent zero-order release profile for over 12 hours is a significant technical challenge. Many existing technologies offer extended release but may not achieve the specific kinetic profile or duration claimed in patent 11,684,632.
A review of the patent family for 11,684,632, including related provisional and non-provisional applications, reveals efforts to broaden the scope to include various APIs and alternative polymer compositions, indicating a strategic intent to secure a comprehensive intellectual property position.
What is the Commercial and Therapeutic Significance of This Patent?
The patent's significance lies in its potential to enable the development of improved drug products for a wide range of therapeutic areas. By providing a reliable and consistent method for sustained drug delivery, it can address unmet clinical needs.
Potential Applications and Benefits:
- Improved Patient Compliance: Reduced dosing frequency translates to better adherence to treatment regimens, particularly for chronic conditions.
- Enhanced Therapeutic Efficacy: Stable plasma concentrations minimize peak-and-trough effects, potentially leading to more consistent therapeutic outcomes and fewer side effects associated with drug level fluctuations.
- Reduced Dosing Burden: For patients requiring multiple daily doses, a once-daily or even less frequent dosing schedule can significantly improve quality of life.
- Application to Diverse APIs: The flexibility of the technology to encapsulate various APIs suggests broad applicability across different therapeutic classes, including cardiovascular drugs, central nervous system agents, and metabolic disorder treatments.
- Market Exclusivity: For any pharmaceutical company utilizing this patented technology, it offers a period of market exclusivity, allowing for a return on investment in drug development and a competitive advantage.
What Are the Potential Business Implications and Strategic Considerations?
The issuance of patent 11,684,632 presents several strategic considerations for pharmaceutical companies, contract development and manufacturing organizations (CDMOs), and investors.
Strategic Considerations:
- Licensing Opportunities: Companies seeking to develop or market drugs with sustained-release profiles may pursue licensing agreements with MediNova Technologies Inc. to utilize the patented technology. This offers a pathway to market without the need for in-house development of novel delivery systems.
- Freedom to Operate (FTO) Analysis: Companies developing or planning to develop similar controlled-release oral dosage forms must conduct thorough FTO analyses to ensure their products do not infringe on patent 11,684,632. This involves careful scrutiny of claimed elements, including polymer types, ratios, manufacturing processes, and release profiles.
- Due Diligence for Investment: Investors considering backing companies in the drug delivery space should evaluate the strength and scope of existing patents, such as 11,684,632, to understand potential competitive advantages or barriers to entry.
- Patent Validity Challenges: Competitors may investigate the patent's validity, looking for prior art or other grounds to challenge its enforceability.
- Pipeline Development: MediNova Technologies Inc. can leverage this patent to build a pipeline of drug candidates utilizing its proprietary delivery system, potentially partnering with pharmaceutical companies for co-development or out-licensing of specific drug-API combinations.
- Manufacturing Partnerships: CDMOs specializing in complex oral dosage forms may seek partnerships to offer manufacturing services based on this technology, requiring specialized equipment and expertise in polymer processing and precision coating.
The patent represents a significant asset for MediNova Technologies Inc. and a key piece of intellectual property within the drug delivery sector. Its claims are specific enough to provide strong protection while allowing for adaptation to various APIs, making it a valuable technology for future pharmaceutical innovation.
Key Takeaways
- Patent 11,684,632 protects a specific multi-layered polymer matrix for sustained-release oral dosage forms, utilizing an osmotic release mechanism.
- Key claims define the dosage form's composition, manufacturing process, and a zero-order drug release profile for at least 12 hours.
- The invention's novelty lies in its specific polymer combinations, pore formation technique, and demonstrated extended zero-order release kinetics.
- The technology offers potential benefits including improved patient compliance, enhanced therapeutic efficacy, and reduced dosing frequency across a broad range of APIs.
- Strategic considerations include licensing opportunities, freedom to operate assessments, and potential patent validity challenges.
Frequently Asked Questions
-
What is the primary advantage of the drug delivery system described in patent 11,684,632 over traditional immediate-release formulations?
The primary advantage is its ability to achieve a sustained, controlled release of the active pharmaceutical ingredient (API) over an extended period, typically 12 hours or more. This leads to more stable plasma concentrations of the drug, potentially improving therapeutic efficacy and patient compliance by reducing the required dosing frequency.
-
Does patent 11,684,632 cover the API itself, or only the delivery mechanism?
The patent exclusively covers the novel drug delivery system. It protects the specific composition and structure of the sustained-release oral dosage form, including its multi-layered polymer matrix, coating, and pore formation. It does not claim the API itself.
-
What specific types of biodegradable polymers are mentioned in the patent, and why are they important?
The patent mentions combinations of biodegradable polymers, including poly(lactic-co-glycolic acid) (PLGA) with specific lactide:glycolide ratios and molecular weights, often in conjunction with polymers like hydroxypropyl methylcellulose (HPMC) or poly(vinyl alcohol) (PVA). These polymers are critical for forming the core matrix, controlling the swelling and erosion rates, and thereby regulating the release of the API through an osmotic mechanism.
-
How is the drug release controlled in the dosage form described by patent 11,684,632?
The drug release is controlled by an osmotic mechanism. A semipermeable membrane coating surrounds a core containing the API and specific polymers. Water enters the core through the semipermeable membrane, creating osmotic pressure. This pressure then pushes the dissolved API out through one or more precisely formed pores in the coating, resulting in a controlled, sustained release rate.
-
What are the potential implications for generic drug manufacturers seeking to develop products with similar extended-release profiles?
Generic manufacturers intending to produce drugs with similar extended-release characteristics must conduct rigorous freedom-to-operate (FTO) analyses to ensure their proposed formulations and manufacturing processes do not infringe on the specific claims of patent 11,684,632. This includes examining the polymer composition, ratios, coating thickness, pore characteristics, and the demonstrated in vitro release profile.
Citations
[1] MediNova Technologies Inc. (2023). US Patent 11,684,632 B2: Sustained-release oral dosage form and method of manufacturing the same. United States Patent and Trademark Office.
[2] United States Pharmacopeia. (n.d.). USP Apparatus 2 (Paddle Apparatus) general chapter.
More… ↓
⤷ Start Trial
|
